The debate over three drugs for diabetic macular edema, Eylea, Avastin and Lucentis, has been going on for quite some time. While all three are effective treatments for diabetic macular edema (DME), Eylea certainly has an edge over Avastin in DME patients with moderate or worse vision loss, say with a visual acuity of 20/50 or worse, says a study.